Key Dates

Related Announcements

RFA-HL-23-010 - Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)

RFA-HL-23-011 - Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)

RFA-HL-23-012 - Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)

RFA-HL-23-013 - Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)

RFA-HL-23-014 - Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)

NOT-HL-22-016 - Notice of Application Due Date Changes for RFA-HL-23-011,"Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)"

NOT-HL-22-017 - Notice of Application Due Date Changes for RFA-HL-23-012, "Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)"

NOT-HL-22-018 - Application Due Date Changes for RFA-HL-23-013, "Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)"

NOT-HL-22-019 - Application Due Date Changes for RFA-HL-23-014, "Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33)"

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to alert potential applicants to a change in application and submission information and in key dates for RFA-HL-23-010, "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)".

The following section of RFA-HL-23-010, Part 2. Full Text of Announcement Section IV has been modified to remove the following language:

Milestones, timeline and project managment plan (required)

The filename "Milestones, timeline and Project managment plan.pdf" should be used. The attachment may not exceed three pages.

Currently Reads:

Section IV. Application and Submission Information

PHS 398 Research Plan
Research Strategy

Milestones, timeline and project managment plan (required)

The filename "Milestones, timeline and Project managment plan.pdf" should be used. The attachment may not exceed three pages.

Milestones: Define milestones that are specific, measurable, achievable, relevant, and time-bound. The milestones should allow program staff to assess progress during the period of the award. Specific aims or a list of activities are not considered milestones. Describe the milestones that need to be reached in the R33 phase to address the specific aims and ensure the successful completion of the entire project.

Modified To Read:

Section IV. Application and Submission Information

PHS 398 Research Plan
Research Strategy

Milestones: Define milestones that are specific, measurable, achievable, relevant, and time-bound. The milestones should allow program staff to assess progress during the period of the award. Specific aims or a list of activities are not considered milestones. Describe the milestones that need to be reached in the R33 phase to address the specific aims and ensure the successful completion of the entire project.

The following changes are made to Key Dates:

Current dates:

Revised dates (in bold italics):

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries regarding this Notice to:

Mike Pieck, Ph.D.
Telephone: 301-827-7986
Email: [email protected]